866-997-4948(US-Canada Toll Free)

Lead Generation Strategies and Technologies in Drug Development - Emerging Techniques Such as Antisense Technology Will Allow Innovators to Minimize Costs

Published By :

GBI Research

Published Date : Jun 2011

Category :

Biotechnology

No. of Pages : 77 Pages


GBI Research has released its latest report, Lead Generation Strategies and Technologies in Drug Development - Emerging Techniques Such as Antisense Technology Will Allow Innovators to Minimize Costs that provides key data, information and analysis of the major trends and developments in the drug devleopment business. The report provides a comprehensive insight into key technological developments, new approaches in lead generation and various technologies developed to accelerate it.The report also provides key alliances and collaborations in the industry to minimize costs and maximize productivity. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Researchs team of industry experts.

Scope

The scope of the report includes - 

  • Key technological developments and new approaches including case studies.
  • Case studies of new technologies and their implementation by companies in drug development industry
  • Key drivers and restraints that have a significant impact on the market.
  • Competitive benchmarking of leading CROs, covering their offerings and recent deals in drug development

Reasons to buy

The report will enhance your decision making capability. It will allow you to - 

  • Compare the key capabilities and models of major technology solution providers with your requirements and optimize your R&D costs
  • Develop market entry and market expansion strategies by identifying the key drivers and challenges in the global drug development market
  • Develop effective strategies to maximize the advantages through the understanding of drug development and business models.
Table of Contents

1 Table of Contents

1 Table of Contents 4
1.1 List of Tables 6
1.2 List of Figures 7

2 Introduction 9
2.1 GBI Report Guidance 9

3 The Drug Discovery Process: Defining Lead Generation 10
3.1 Process of Early Preclinical Drug Discovery 10
3.1.1 Pre-Discovery 10
3.1.2 Target Identification 11
3.1.3 Target Validation 12
3.1.4 Lead Identification 12
3.1.5 Early Safety Tests 13
3.1.6 Lead Optimization 13
3.1.7 Preclinical Testing 14
3.2 Hit to Lead - Identifying Possible Structure 15
3.2.1 Strategies Used In Generating Potential Lead from Identified Hits 15
3.3 Role of Lead Generation in the Path of Drug Development 18

4 Lead Generation Strategies in the Pharmaceutical Industry 19
4.1 Massive Decline in Sales - Dependence on Blockbuster Drugs 19
4.2 Need to Accelerate Lead Generation Process 20
4.2.1 Stricter FDA Rules and Regulations for Drug Approval 20
4.2.2 Penetration of Aggressive Generic Companies 21
4.2.3 The Economic Impact of Compound Attrition at Various Stages of Lead Discovery 23
4.2.4 Drought in the R&D Pipeline Products (Low R&D Productivity) 25
4.3 HTS Solutions for ADME Testing 27
4.3.1 In Vitro Studies of Drug Absorption 27
4.3.2 In Vitro Studies of Protein Binding 29
4.4 Fragment-Based Drug Discovery 30
4.4.1 Differences Between HTS and FBDD 31
4.4.2 Advantages of Fragment-Based Drug Design over High-Throughput Screening 31
4.4.3 Applications of Mass Spectrometry in Fragment Library Screening 33
4.4.4 Recent Advances in Structure-Based Fragment Docking and Virtual Screening 34
4.4.5 Novel Strategy for the Design of a Fluorinated Fragment Library, Named LEF (Local Environment of Fluorine) 35
4.4.6 Ligand-Based Approach to In Silico Pharmacology 38
4.5 Antisense Technology as a Strategy 38
4.5.1 Isis Pharmaceuticals 38
4.5.2 CytRx Laboratories 38
4.6 Iterative Focused Screening as a Strategy 39
4.6.1 Merck Frosst Canada 39

5 Emerging Technology in Lead Generation 40
5.1 Improving High Throughput Screening 40
5.1.1 Overview 40
5.1.2 Case Study 40
5.1.3 Improving In Vitro Assays for HTS 41
5.1.4 Whole Animal Imaging and Microscopy 41
5.2 The Parallel Synthesis Approach 42
5.2.1 In Vitro Methods 42
5.2.2 In Silico Methods - Structure-Toxicity Relationships 42
5.3 Computerized Combinatorial Chemistry and 3D Molecular Modeling 43
5.3.1 Overview 43
5.3.2 Service Providers 44
5.3.3 Case Studies 45
5.4 Molecular Bioimaging 46
5.4.1 Overview 46
5.4.2 Service Providers 46
5.4.3 Case Study 46
5.5 Omics-Technology and Bioinformatics 47
5.5.1 Overview 47
5.5.2 Service Providers 47
5.5.3 Case Study 48

6 Lead Generation Now and in the Future 50
6.1 R&D Models: Influence on Lead Generation 50
6.1.1 Recent Technology Developments 50
6.2 A Novel Technology to Enhance Fragment-Based Drug Discovery 53
6.2.1 ZoBios Target Immobilized NMR Spectroscopy Method for Fragment-Based Drugs 53

7 Pharmaceutical Outsourcing as a Strategy to Accelerate Lead Generation 55
7.1 Early Stage Drug Development Outsourcing 55
7.1.1 Strategic or Tactical Advantages of Outsourcing 55
7.1.2 Case Study 56
7.2 Emerging Regions in the Global Contract Research Outsourcing Market for Early Stage Drug Development 57
7.2.1 Latin America 57
7.2.2 Central and Eastern Europe (CEE) 58
7.2.3 India 59
7.2.4 China 61

8 Major Contract Research Organizations in Drug Discovery 63
8.1 Cyprotex Discovery Ltd. 63
8.1.1 Business Overview 63
8.1.2 Services 63
8.2 Shanghai ChemPartner 64
8.2.1 Business Overview 64
8.2.2 Services 64
8.3 Covance, Inc. 65
8.3.1 Business Overview 65
8.3.2 Services 65
8.4 Caliper Life Sciences 66
8.4.1 Business Overview 66
8.4.2 Services 66
8.5 GVK BIO 67
8.5.1 Business Overview 67
8.5.2 Services 67
8.6 Jubilant Biosys 68
8.6.1 Business Overview 68
8.6.2 Services 68
8.7 Advinus Therapeutics 69
8.7.1 Business Overview 69
8.7.2 Services 69
8.8 ITR Canada 70
8.8.1 Business Overview 70
8.8.2 Services 70
8.9 MD Biosciences 71
8.9.1 Business Overview 71
8.9.2 Services 71
8.10 PPD, Inc. 72
8.10.1 Business Overview 72
8.10.2 Services 72
8.11 Ricerca Biosciences, LLC 73
8.11.1 Business Overview 73
8.11.2 Services 73
8.12 MPI Research 74
8.12.1 Business Overview 74
8.12.2 Services 74

9 Lead Generation Strategies and Technologies in Drug Discovery - Appendix 75
9.1 Market Definitions 75
9.2 Abbreviations 75
9.3 Research Methodology 76
9.3.1 Coverage 76
9.3.2 Secondary Research 76
9.3.3 Primary Research 76
9.3.4 Expert Panel Validation 77
9.4 Contact Us 77
9.5 Disclaimer 77
9.6 Sources 77

List of Table


Table 1: Lead Generation Strategies and Technologies in Drug Discovery, Top 20 Patent Expirations During 2010-2014, Based on US Sales in Dollars 19
Table 2: Lead Generation Strategies and Technologies in Drug Discovery, Comparison of Microdialysis with Ultrafilteration 29
Table 3: Lead Generation Strategies and Technologies in Drug Discovery, Recent Success Stories in Virtual Screening 35
Table 4: Lead Generation Strategies and Technologies in Drug Discovery, Application of SPR by Noxxon Pharmaceutical 37

List of Chart


Figure 1: Lead Generation Strategies and Technologies in Drug Discovery, Life Cycle of a New Drug 10
Figure 2: Lead Generation Strategies and Technologies in Drug Discovery, Drug Discovery Process 11
Figure 3: Lead Generation Strategies and Technologies in Drug Discovery, Applications of Lead Generation Process 12
Figure 4: Lead Generation Strategies and Technologies in Drug Discovery, Pathways For Optimizing Lead Through Screening 13
Figure 5: Lead Generation Strategies and Technologies in Drug Discovery, Effective Lead Optimization 14
Figure 6: Lead Generation Strategies and Technologies in Drug Discovery, Hit Evolution Form Drug-Like Hit 16
Figure 7: Lead Generation Strategies and Technologies in Drug Discovery, Isosteric Replacement Form Drug-Like Hit 16
Figure 8: Lead Generation Strategies and Technologies in Drug Discovery, Hit-Fragmentation In Lead Generation 17
Figure 9: Lead Generation Strategies and Technologies in Drug Discovery, Target Preference In Drug Discovery 18
Figure 10: Lead Generation Strategies and Technologies in Drug Discovery, Decline In NME Approvals By The FDA, 1996-2010 20
Figure 11: Lead Generation Strategies and Technologies in Drug Discovery, Original Abbreviated New Drug Application (ANDA) Approvals During 2001-2009 21
Figure 12: Lead Generation Strategies and Technologies in Drug Discovery, Decision Check Points At Various Stages In Lead Generation 23
Figure 13: Lead Generation Strategies and Technologies in Drug Discovery, Pharmaceutical and Biotech R&D Expenditure ($bn) versus Number of NME/BLA Approvals, the US, 1995-2009 24
Figure 14: Lead Generation Strategies and Technologies in Drug Discovery, Proportion of LCM Projects in the Late-Stage Development Pipeline by Therapeutic Area, 2010 25
Figure 15: Lead Generation Strategies and Technologies in Drug Discovery, Comparison of CAGR of R&D Expenditure versus Turnover for the Top Five Companies, 2003-2008 26
Figure 16: Lead Generation Strategies and Technologies in Drug Discovery, Effect of First-Pass Metabolism In Bioavailability 28
Figure 17: Lead Generation Strategies and Technologies in Drug Discovery, HTS ADME Assay 28
Figure 18: Lead Generation Strategies and Technologies in Drug Discovery, ADMET Screening Technology 30
Figure 19: Lead Generation Strategies and Technologies in Drug Discovery, Evotecs Approach of Identifying Novel BACE 1 Inhibitor Using Fragment-Based Approach 32
Figure 20: Mass Spectrometry in Drug Library Screening 33
Figure 21: Lead Generation Strategies and Technologies in Drug Discovery, Advantages of Label-Free Cell-Based Assay 36
Figure 22: Lead Generation Strategies and Technologies in Drug Discovery, Benefits And Challenges In Imaging Technique 41
Figure 23: Lead Generation Strategies and Technologies in Drug Discovery, Service Providers In Combinatorial Chemistry And 3D Molecular Modeling 45
Figure 24: Lead Generation Strategies and Technologies in Drug Discovery, Service Providers Of Omics Technology And Bioinformatics 48
Figure 25: Lead Generation Strategies and Technologies in Drug Discovery, Strategic Or Tactical Advantages In Early Stage Drug Development Outsourcing 55
Figure 26: Lead Generation Strategies and Technologies in Drug Discovery, Outsourcing to Latin America 57
Figure 27: Lead Generation Strategies and Technologies in Drug Discovery, Outsourcing to Central and Eastern Europe(CEE) 58
Figure 28: Lead Generation Strategies and Technologies in Drug Discovery, Outsourcing to India 59
Figure 29: Lead Generation Strategies and Technologies in Drug Discovery, Outsourcing Scenario in India 60
Figure 30: Lead Generation Strategies and Technologies in Drug Discovery, Outsourcing to China 61
Figure 31: Lead Generation Strategies and Technologies in Drug Discovery, Cyprotex - Corporate Profile 63
Figure 32: Lead Generation Strategies and Technologies in Drug Discovery, Shanghai ChemPartner - Corporate Profile 64
Figure 33: Lead Generation Strategies and Technologies in Drug Discovery, Covance, Inc - Corporate Profile 65
Figure 34: Lead Generation Strategies and Technologies in Drug Discovery, Caliper Life Sciences, Inc - Corporate Profile 66
Figure 35: Lead Generation Strategies and Technologies in Drug Discovery, GVK BIO - Corporate Profile 67
Figure 36: Lead Generation Strategies and Technologies in Drug Discovery, Jubilant Biosys, Inc - Corporate Profile 68
Figure 37: Lead Generation Strategies and Technologies in Drug Discovery, Advinus Therapeutics, Inc - Corporate Profile 69
Figure 38: Lead Generation Strategies and Technologies in Drug Discovery, ITR Canada, Inc - Corporate Profile 70
Figure 39: Lead Generation Strategies and Technologies in Drug Discovery, MD Biosciences - Corporate Profile 71
Figure 40: Lead Generation Strategies and Technologies in Drug Discovery, PPD, Inc - Corporate Profile 72
Figure 41: Lead Generation Strategies and Technologies in Drug Discovery, Ricerca Biosciences, LLC - Corporate Profile 73
Figure 42: Lead Generation Strategies and Technologies in Drug Discovery, MPI Research - Corporate Profile 74

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *